Scarica l'app Stockscreener
13.36
1.69%
-0.23
Dopo l'orario di chiusura:
13.34
-0.02
-0.15%
Hutchmed China Limited Adr Borsa (HCM) Ultime notizie
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
HUTCHMED (Nasdaq: HCM) launches registrational Phase III HMPL-760 lymphoma trial in China - Stock Titan
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewswire Inc.
HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su - Stock Titan
HUTCHMED (China) Limited Sponsored ADR $HCM Stake Trimmed by Schroder Investment Management Group - MarketBeat
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
HUTCHMED (HCM) vests 726,317 LTIP shares to CEO and CFO - Stock Titan
TAZVERIK cancer drug withdrawn; HUTCHMED (HCM) ends China trials - Stock Titan
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - ChartMill
CLSA Cuts TP of HUTCHMED (00013.HK) to HKD30.4; Rating Outperform - AASTOCKS.com
Intended Retirement of Independent Non-executive Director and changes of composition of board committees - ChartMill
HUTCHMED (NASDAQ: HCM) plans INED retirement, reshapes board roles - Stock Titan
HUTCHMED H2 Earnings Call Highlights - Yahoo Finance
Food & Life Companies (3563.JP) Plunges 14% Following Alleged Parasite Egg Discovery at Beijing's Sushiro - AASTOCKS.com
[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan
HUTCHMED Reports 2025 Full Year Results and Business Updates - GlobeNewswire
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – What’s Next? - Defense World
Brokerages Set QCR Holdings, Inc. (NASDAQ:QCRH) PT at $102.25 - Defense World
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Analysts - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
JPMorgan Chase & Co. Has $729.86 Million Stock Holdings in iShares ESG Aware MSCI EAFE ETF $ESGD - Defense World
Glenview Trust Co Raises Stock Position in Vanguard Intermediate-Term Corporate Bond ETF $VCIT - Defense World
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
UOB Kay Hian Favors ALI HEALTH, PA GOODDOCTOR; AI Innovation & National Policies Drive CN Internet Healthcare Sector - AASTOCKS.com
Labcorp Holdings Inc. $LH Stake Lessened by Jensen Investment Management Inc. - Defense World
Kayne Anderson Energy Infrastructure Fund (NYSE:KYN) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Cipher Mining (NASDAQ:CIFR) Shares Gap Up – Still a Buy? - Defense World
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $20.88 - Defense World
BOCOMI Expects Pharma Sector to Continue Stable Improvement This Yr, Recommends Seeking Undervalued Pharma - AASTOCKS.com
1.58%
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):